To operate successfully within the exosome marketplace, it is vital to assess novel opportunities for product development. Currently, there are five market segments that compose the market for stem cell exosomes. These market segments include: Exosome therapeutics, diagnostic tools, research tools, cosmeceuticals, and manufacturing technologies. [Read more…]
Regenerelle® Issues Response to FDA Untitled Letter
Rochester, NY — September 8, 2025 — Regenerelle®, a global leader in the manufacturing and distribution of Wharton’s Jelly Mesenchymal Stromal Cells (WJ-MSCs) and exosomes derived from WJ-MSCs, today announced the public release of its full response to the U.S. Food and Drug Administration (FDA) Untitled Letter dated May 22, 2023.
The disclosure is being made by AT Venture Center, the parent company of Regenerelle, LLC, the regenerative biotherapeutic manufacturing and distribution arm of the company providing stem cells and exosome products to its subsidiaries and distributors serving an extensive connected network of more than 4,000 regenerative medicine and aesthetics professionals worldwide, including MedSpas, orthopedic and pain clinics, wound care centers, and aesthetic practices. [Read more…]
Precision Over Hype: Biogenomics’ Genovia Sets a New Standard in Exosome-Based Regenerative Aesthetics
Los Angeles, CA – September 4, 2025 – As industry scrutiny intensifies over cosmetic products making bold but unverified “exosome” claims, Biogenomics, a biotech company advancing regenerative aesthetics, has announced performance breakthroughs for its flagship innovation, Genovia. Unlike competitors who emphasize inflated particle counts, Genovia is engineered through a patented lactoferrin-enhanced process that delivers scientifically validated quality, safety, and functional performance.
“Exosomes aren’t about chasing numbers — they’re about results providers can trust and patients can see,” said a Biogenomics spokesperson. “That’s the standard Genovia delivers.” [Read more…]
From Bench to Bedside: The Global Market for Exosome Therapeutics
Exosomes have incredible properties that enable researchers to engineer exosomes as carriers for the delivery of drugs, as well as perfectly target tissues of interest, while evading or modulating immune responses. Today, drug delivery and development of exosome-mediated therapies is a growing market segment, with over 60 companies forging ahead in this field. Many of the recent advances in exosome research are technology-based and this helps researchers to quantify exosome cargoes and subtypes, allowing for the tracking of exosomes with remarkable precision. This is helping companies to regulate exosome drug dosage and delivery, as well as delivering effective treatments for hard-to-treat diseases, such as cancer and neurodegenerative diseases. [Read more…]
Future Medical Products LLC Announces the Launch of PBME Topical™ (Pure Bone Marrow Exosomes)
July 24, 2025, St. Louis, Missouri — Future Medical Products LLC is pleased to announce the launch of PBME Topical (“Pure Bone Marrow Exosomes”). PBME Topical is a cosmetic product in compliance with the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).
PBME Topical consists of isolated exosomes from mesenchymal stem cells, the most studied cell in science. These exosomes are composed of phospholipid bilayers with transmembrane proteins and receptors, integrated growth factors, in addition to micro-RNA and messenger-RNA. Exosomes are naturally found in every part of the body, but the source of the exosomes intended for aesthetics, as well as regenerative medicine, is critical. Bone marrow exosomes are considered by some to be the purest form of stem cell therapy without the cell. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 27
- Next Page »